Paolo Tarantino: Fixed dose of capecitabine vs standard dose for Metastatic Breast Cancer
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, posted on X about recent paper by Qamar J. Khan et al., titled “Randomized Trial of Fixed-Dose Capecitabine Compared With Standard-Dose Capecitabine in Metastatic Breast Cancer: X-7/7 Trial” published on Journal of Clinical Oncology Advcances.
Authors: Qamar J. Khan, Colleen Bohnenkamp, Taylor E. Monson, Milind A. Phadnis, Lauren Clark, Holly E. Smith, Vinay Raja, Manana Elia, Anne O’Dea, Mark R. Fesen, Gregory J. Crane, Lauren E. Nye, Joaquina C. Baranda, Robert E. Pluenneke, Marc Hoffmann, Raed Moh’d Taiseer Al-Rajabi, Anup Kasi, Richard J. McKittrick, Laura Mitchell, Stephanie LaFaver, Priyanka Sharma.
“X-7/7 randomized trial out on JCO. A fixed 1500mg BID dose of capecitabine 7d on-7d off was as active and less toxic than the standard dose/regimen for Metastatic Breast Cancer. Caveats: small trial, ORR favored standard dose. Should be considered for frail patients.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023